基于脂肪抑制 T2 加权磁共振成像预测多发性骨髓瘤高风险细胞遗传学状态的放射学提名图

IF 3.4 2区 医学 Q2 Medicine
Suwei Liu , Haojie Pan , Shenglin Li , Zhengxiao Li , Jiachen Sun , Tiezhu Ren , Junlin Zhou
{"title":"基于脂肪抑制 T2 加权磁共振成像预测多发性骨髓瘤高风险细胞遗传学状态的放射学提名图","authors":"Suwei Liu ,&nbsp;Haojie Pan ,&nbsp;Shenglin Li ,&nbsp;Zhengxiao Li ,&nbsp;Jiachen Sun ,&nbsp;Tiezhu Ren ,&nbsp;Junlin Zhou","doi":"10.1016/j.jbo.2024.100617","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale and Objectives</h3><p>Radiomics has demonstrated potential in predicting the cytogenetic status of multiple myeloma (MM). However, the role of single-sequence radiomic nomograms in predicting the high-risk cytogenetic (HRC) status of MM remains underexplored. This study aims to develop and validate radiomic nomograms based on fat-suppressed T2-weighted images (T2WI-FS) for predicting MM’s HRC status, facilitating pre-treatment decision-making and prognostic assessment.</p></div><div><h3>Materials and methods</h3><p>A cohort of 159 MM patients was included, comprising 71 HRC and 88 non-HRC cases. Regions of interest within the most significant tumor lesions on T2WI-FS images were manually delineated, yielding 1688 features. Fourteen radiomic features were selected using 10-fold cross-validation, employing methods such as variance thresholds, Student’s <em>t</em>-test, redundancy analysis, and least absolute shrinkage and selection operator (LASSO). Logistic regression was utilized to develop three prediction models: a clinical model (model 1), a T2WI-FS radiomic model (model 2), and a combined clinical-radiomic model (model 3). Receiver operating characteristic (ROC) curves evaluated and compared the diagnostic performance of these models. Kaplan-Meier survival analysis and log-rank tests assessed the prognostic value of the radiomic nomograms.</p></div><div><h3>Results</h3><p>Models 2 and 3 demonstrated significantly greater diagnostic efficacy compared to model 1 (<em>p</em> &lt; 0.05). The areas under the ROC curve for models 1, 2, and 3 were as follows: training set—0.650, 0.832, and 0.846; validation set—0.702, 0.730, and 0.757, respectively. Kaplan-Meier survival analysis indicated comparable prognostic values between the radiomic nomogram and MM cytogenetic status, with log-rank test results (<em>p</em> &lt; 0.05) and concordance indices of 0.651 and 0.659, respectively; z-score test results were not statistically significant (<em>p</em> = 0.153). Additionally, Kaplan-Meier analysis revealed that patients in the non-HRC group, low-RS group, and aged ≤ 60 years exhibited the longest overall survival, while those in the HRC group, high-RS group, and aged &gt; 60 years demonstrated the shortest overall survival (<em>p</em> = 0.004, Log-rank test).</p></div><div><h3>Conclusions</h3><p>Radiomic nomograms are capable of predicting the HRC status in MM. The cytogenetic status, radiomics model Rad score, and age collectively influence the overall survival of MM patients. These factors potentially contribute to pre-treatment clinical decision-making and prognostic assessment.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000976/pdfft?md5=4c6f93c766a290f1194b28aa9b193d20&pid=1-s2.0-S2212137424000976-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging\",\"authors\":\"Suwei Liu ,&nbsp;Haojie Pan ,&nbsp;Shenglin Li ,&nbsp;Zhengxiao Li ,&nbsp;Jiachen Sun ,&nbsp;Tiezhu Ren ,&nbsp;Junlin Zhou\",\"doi\":\"10.1016/j.jbo.2024.100617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Rationale and Objectives</h3><p>Radiomics has demonstrated potential in predicting the cytogenetic status of multiple myeloma (MM). However, the role of single-sequence radiomic nomograms in predicting the high-risk cytogenetic (HRC) status of MM remains underexplored. This study aims to develop and validate radiomic nomograms based on fat-suppressed T2-weighted images (T2WI-FS) for predicting MM’s HRC status, facilitating pre-treatment decision-making and prognostic assessment.</p></div><div><h3>Materials and methods</h3><p>A cohort of 159 MM patients was included, comprising 71 HRC and 88 non-HRC cases. Regions of interest within the most significant tumor lesions on T2WI-FS images were manually delineated, yielding 1688 features. Fourteen radiomic features were selected using 10-fold cross-validation, employing methods such as variance thresholds, Student’s <em>t</em>-test, redundancy analysis, and least absolute shrinkage and selection operator (LASSO). Logistic regression was utilized to develop three prediction models: a clinical model (model 1), a T2WI-FS radiomic model (model 2), and a combined clinical-radiomic model (model 3). Receiver operating characteristic (ROC) curves evaluated and compared the diagnostic performance of these models. Kaplan-Meier survival analysis and log-rank tests assessed the prognostic value of the radiomic nomograms.</p></div><div><h3>Results</h3><p>Models 2 and 3 demonstrated significantly greater diagnostic efficacy compared to model 1 (<em>p</em> &lt; 0.05). The areas under the ROC curve for models 1, 2, and 3 were as follows: training set—0.650, 0.832, and 0.846; validation set—0.702, 0.730, and 0.757, respectively. Kaplan-Meier survival analysis indicated comparable prognostic values between the radiomic nomogram and MM cytogenetic status, with log-rank test results (<em>p</em> &lt; 0.05) and concordance indices of 0.651 and 0.659, respectively; z-score test results were not statistically significant (<em>p</em> = 0.153). Additionally, Kaplan-Meier analysis revealed that patients in the non-HRC group, low-RS group, and aged ≤ 60 years exhibited the longest overall survival, while those in the HRC group, high-RS group, and aged &gt; 60 years demonstrated the shortest overall survival (<em>p</em> = 0.004, Log-rank test).</p></div><div><h3>Conclusions</h3><p>Radiomic nomograms are capable of predicting the HRC status in MM. The cytogenetic status, radiomics model Rad score, and age collectively influence the overall survival of MM patients. These factors potentially contribute to pre-treatment clinical decision-making and prognostic assessment.</p></div>\",\"PeriodicalId\":48806,\"journal\":{\"name\":\"Journal of Bone Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2212137424000976/pdfft?md5=4c6f93c766a290f1194b28aa9b193d20&pid=1-s2.0-S2212137424000976-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212137424000976\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212137424000976","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

原理与目的放射组学在预测多发性骨髓瘤(MM)的细胞遗传学状态方面已显示出潜力。然而,单序列放射组学提名图在预测多发性骨髓瘤高危细胞遗传学(HRC)状态方面的作用仍未得到充分探索。本研究旨在开发和验证基于脂肪抑制T2加权图像(T2WI-FS)的放射学提名图,以预测MM的HRC状态,从而促进治疗前决策和预后评估。对 T2WI-FS 图像上最重要的肿瘤病灶内的感兴趣区进行人工划定,共获得 1688 个特征。采用方差阈值、学生 t 检验、冗余分析和最小绝对收缩和选择算子(LASSO)等方法,通过 10 倍交叉验证筛选出 14 个放射学特征。利用逻辑回归建立了三个预测模型:临床模型(模型 1)、T2WI-FS 放射模型(模型 2)和临床-放射联合模型(模型 3)。接收者操作特征(ROC)曲线评估并比较了这些模型的诊断性能。卡普兰-梅耶生存分析和对数秩检验评估了放射学提名图的预后价值。结果与模型 1 相比,模型 2 和模型 3 的诊断效果显著更高(p < 0.05)。模型 1、2 和 3 的 ROC 曲线下面积分别为:训练集-0.650、0.832 和 0.846;验证集-0.702、0.730 和 0.757。卡普兰-梅耶生存分析表明,放射学提名图与 MM 细胞遗传学状态的预后价值相当,对数秩检验结果(p < 0.05)和一致性指数分别为 0.651 和 0.659;z-score 检验结果无统计学意义(p = 0.153)。此外,Kaplan-Meier分析显示,非HRC组、低RS组和年龄小于60岁的患者总生存期最长,而HRC组、高RS组和年龄大于60岁的患者总生存期最短(P = 0.004,对数秩检验)。细胞遗传学状态、放射组学模型 Rad 评分和年龄共同影响 MM 患者的总生存率。这些因素可能有助于治疗前的临床决策和预后评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging

Rationale and Objectives

Radiomics has demonstrated potential in predicting the cytogenetic status of multiple myeloma (MM). However, the role of single-sequence radiomic nomograms in predicting the high-risk cytogenetic (HRC) status of MM remains underexplored. This study aims to develop and validate radiomic nomograms based on fat-suppressed T2-weighted images (T2WI-FS) for predicting MM’s HRC status, facilitating pre-treatment decision-making and prognostic assessment.

Materials and methods

A cohort of 159 MM patients was included, comprising 71 HRC and 88 non-HRC cases. Regions of interest within the most significant tumor lesions on T2WI-FS images were manually delineated, yielding 1688 features. Fourteen radiomic features were selected using 10-fold cross-validation, employing methods such as variance thresholds, Student’s t-test, redundancy analysis, and least absolute shrinkage and selection operator (LASSO). Logistic regression was utilized to develop three prediction models: a clinical model (model 1), a T2WI-FS radiomic model (model 2), and a combined clinical-radiomic model (model 3). Receiver operating characteristic (ROC) curves evaluated and compared the diagnostic performance of these models. Kaplan-Meier survival analysis and log-rank tests assessed the prognostic value of the radiomic nomograms.

Results

Models 2 and 3 demonstrated significantly greater diagnostic efficacy compared to model 1 (p < 0.05). The areas under the ROC curve for models 1, 2, and 3 were as follows: training set—0.650, 0.832, and 0.846; validation set—0.702, 0.730, and 0.757, respectively. Kaplan-Meier survival analysis indicated comparable prognostic values between the radiomic nomogram and MM cytogenetic status, with log-rank test results (p < 0.05) and concordance indices of 0.651 and 0.659, respectively; z-score test results were not statistically significant (p = 0.153). Additionally, Kaplan-Meier analysis revealed that patients in the non-HRC group, low-RS group, and aged ≤ 60 years exhibited the longest overall survival, while those in the HRC group, high-RS group, and aged > 60 years demonstrated the shortest overall survival (p = 0.004, Log-rank test).

Conclusions

Radiomic nomograms are capable of predicting the HRC status in MM. The cytogenetic status, radiomics model Rad score, and age collectively influence the overall survival of MM patients. These factors potentially contribute to pre-treatment clinical decision-making and prognostic assessment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
2.90%
发文量
50
审稿时长
34 days
期刊介绍: The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer. As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject. The areas covered by the journal include: Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment) Preclinical models of metastasis Bone microenvironment in cancer (stem cell, bone cell and cancer interactions) Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics) Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management) Bone imaging (clinical and animal, skeletal interventional radiology) Bone biomarkers (clinical and translational applications) Radiotherapy and radio-isotopes Skeletal complications Bone pain (mechanisms and management) Orthopaedic cancer surgery Primary bone tumours Clinical guidelines Multidisciplinary care Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信